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Abstract
Background: The human papillomavirus (HPV) vaccines have been widely introduced in immunization programs
worldwide, however, it is not accepted in mainland China. We aimed to investigate the awareness and knowledge
about HPV vaccines and explore the acceptability of vaccination among the Chinese population.
Methods: A meta-analysis was conducted across two English (PubMed, EMBASE) and three Chinese (China
National Knowledge Infrastructure, Wan Fang Database and VIP Database for Chinese Technical Periodicals)
electronic databases in order to identify HPV vaccination studies conducted in mainland China. We conducted and
reported the analysis in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines.
Results: Fifty-eight unique studies representing 19 provinces and municipalities in mainland China were assessed.
The pooled awareness and knowledge rates about HPV vaccination were 15.95 % (95 % CI: 12.87–19.29, I2 = 98.9 %)
and 17.55 % (95 % CI: 12.38–24.88, I2 = 99.8 %), respectively. The female population (17.39 %; 95 % CI: 13.06–22.20,
I2 = 98.8 %) and mixed population (18.55 %; 95 % CI: 14.14–23.42, I2 = 98.8 %) exhibited higher HPV vaccine awareness
than the male population (1.82 %; 95 % CI: 0.50–11.20, I2 = 98.5 %). Populations of mixed ethnicity had lower HPV
vaccine awareness (9.61 %; 95 % CI: 5.95–14.03, I2 = 99.0 %) than the Han population (20.17 %; 95 % CI: 16.42–24.20,
I2 = 98.3 %). Among different regions, the HPV vaccine awareness was higher in EDA (17.57 %; 95 % CI: 13.36–22.21,
I2 = 98.0 %) and CLDA (17.78 %; 95 % CI: 12.18–24.19, I2 = 97.6 %) than in WUDA (1.80 %; 95 % CI: 0.02–6.33, I2 = 98.9 %).
Furthermore, 67.25 % (95 % CI: 58.75–75.21, I2 = 99.8 %) of participants were willing to be vaccinated, while this number
was lower for their daughters (60.32 %; 95 % CI: 51.25–69.04, I2 = 99.2 %). The general adult population (64.72 %; 95 %
CI: 55.57–73.36, I2 = 99.2 %) was more willing to vaccinate their daughters than the parent population (33.78 %; 95 %
CI: 26.26–41.74, I2 = 88.3 %). Safety (50.46 %; 95 % CI: 40.00–60.89, I2 = 96.6 %) was the main concern about vaccination
among the adult population whereas the safety and efficacy (68.19 %; 95 % CI: 53.13–81.52, I2 = 98.6 %) were the main
concerns for unwillingness to vaccinate their daughters.
Conclusions: Low HPV vaccine awareness and knowledge was observed among the Chinese population. HPV vaccine
awareness differed across sexes, ethnicities, and regions. Given the limited quality and number of studies included,
further research with improved study designis necessary.
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Background
Cervical cancer, one of the most common cancers ob-
served in females [1], affects more than 529,000 annually
around the world [2]. More than 85 % of the global
cervical cancer burden occurs in developing countries
[2], with 75,500 incidences reported annually in China.
Human Papillomavirus (HPV) infection is the most
important risk factor for cervical cancer [3]. Although a
single HPV infection can easily be eliminated through
the immune system, malignant transformation of cervical
epithelial cells may be induced in a small proportion of
women affected by persistent virus infection.
Vaccines have always been among the most effective
interventions for infectious diseases [4]. Prophylactic
vaccines of cervical cancer manufactured by Merck
&Co. have been approved by FDA and have been com-
mercially available since 2006 [5]. The approval of vac-
cines for the HPV increased the possibility of eradicating
cervical cancer in the near future. However, it is note-
worthy that awareness of HPV and the general attitude
towards vaccination were crucial factors for acceptance
of vaccination among the population. In addition, in-
creasing number of studies addressing the hesitation to
get vaccinated have been conducted in the recent years,
portraying the challenging and dynamic period of indeci-
siveness concerning HPV vaccination [6].
The HPV vaccine has been widely introduced in the
vaccination programs of Hong Kong, however, is not
popularly accepted in Mainland China at present. In
addition, despite the numerous published studies focus-
ing on the topic of HPV and vaccination in recent years,
there is no comprehensive information concerning the
acceptance and obstacles associated with vaccination
among the population of Mainland China. In order to
develop a practical vaccination program in the future, it
is imperative to assess the level of awareness and know-
ledge about HPV, and the general attitude towards HPV
vaccination among the Chinese population, as they are
important behavioral determinants that will ultimately
affect the acceptance of vaccination among the Chinese
population. Therefore, we conducted a meta-analysis in
order to gain a better understanding of this issue that may
help generate new ideas to make future generalization of
HPV vaccination possible in China.
Methods
Search strategy
The meta-analysis was conducted in compliance with
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) guidelines [7]. The
Chinese literature was searched using the China
National Knowledge Infrastructure (CNKI), Wan Fang
Database and VIP Database for Chinese Technical
Periodicals (VIP) using the keywords “HPV vaccine OR
cervical vaccine”. The literature in English was searched
using PubMed and EMBASE, and relevant studies were
identified with the search terms “HPV OR cervical can-
cer” AND “vaccine OR vaccination OR immunization”
AND “awareness OR knowledge OR acceptability OR
acceptance OR willingness OR perception OR attitude
OR recognition” AND “China OR Chinese.” The publi-
cation time was limited to 2006–2015, as HPV vaccine
was introduced in the world in 2006. Data retrieval was
supplemented by manually searching for the reference
list of key reviews and references from retrieved studies.
No language restriction was imposed.
Selection criteria
The inclusion criteria for the epidemiological studies
were the following: (1)study involved at least one of the
key terms “HPV vaccine awareness”, “knowledge”, and
“acceptability”for any region of Mainland China (exclud-
ing studies conducted in Taiwan, Hong Kong and Macao
due to differencesin socio-economic levels and health
policies between these regions and Mainland China), (2)
original data was available regardless of whether it was
obtained directly from the article or traced from second-
ary data in the article. Studies that examining the effects
of health educational interventions were excluded.
Data extraction
A data abstraction form was constructed after scanning
the selected articles. For each included study, we ex-
tracted the following information: author, publication
year, region, study instrument, study subject (age, sex
and ethnicity), sampling method, sample size (N), the
number of participants for the assessment of HPV vac-
cine awareness, knowledge, and acceptance, or the rate
percentage proportions for these studied factors. We
also extracted the reasons for unwillingness to be vacci-
nated if this information was available. The number of
studied cases(n) and sample size(N) were the two neces-
sary parameters for the calculation of the pooled rates of
HPV vaccine awareness, knowledge, and acceptance of
vaccination in the meta-analysis. In particular, the num-
ber of studied cases (n) was obtained directly from the
original studies or by multiplying the sample sizes (N)
with the proportions (%) associated with the investigated
factors reported in the original studies.
Quality assessment
We employed a flexible appraisal scale suggested by Iain
Crombie [8] for the assessment of the quality of cross-
sectional studies. The scale contains seven indexes: (1)
design is scientific, (2) data collection strategy is reason-
able, (3) sample response rate is reported, (4) samples
can represent the general population well, (5) the re-
search purpose and method is reasonable, (6) the test
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efficiency is reported, (7) the statistical method is rea-
sonable. For each index, the study was scored “1,” “0,”or
“0.5” for “yes,” “no,”or “unclear,” respectively. The max-
imum score in the scale is 7 points, with scores of 6.0–
7.0 points as grade A, scores of 4.0–5.5 points as grade
B, and scores of less than 4.0 points as grade C.
Data analysis
We used “rate” to evaluate the studied items. The
rate for HPV vaccine awareness was calculated by
dividing the number of cases who were aware of HPV
vaccine (n1) by the sample size (N); the rate for HPV
vaccine knowledge was calculated by dividing the
number of cases who knew the relationship between
HPV (vaccine) and cervical cancer (n2) by the sample
size (N); the rate for acceptance to be vaccinated was
calculated by dividing the number of cases who were
willing to get vaccinated (n3) by the sample size (N);
the rate for acceptance of parents to vaccinate their
daughters was calculated by dividing the number of
cases who were willing to vaccinate their daughters
(n4) by the sample size(N); the rate for reasons of
unwillingness to be vaccinated was calculated by div-
iding the number of cases who gave a reason (n5) by
the number of cases who were unwilling to be vacci-
nated (N-n3).
Meta-analysis was conducted using a random effects
model. Given the requirement for normalization of
single rate in meta-analysis, an arcsine transformation
for the original rate was performed to meet the require-
ment [9]. Statistical heterogeneity among the studies was
estimated by Chi-square test at the significance level of
P < 0.10, and using the I-square (I2) statistic to quantify
the heterogeneity of the results. Publication bias was
detected by Egger’s test (P < 0.05 was considered statisti-
cally significant) [10]. R statistical software (Version
2.11.1) was used for all the calculations.
Consent statement
As this study was a meta-analysis, we did not include
any humans and animals. This study was approved by




Our search returned 1683 articles. A flow diagram of the
selection process is shown in Fig. 1. Of the original arti-
cles, 1561 articles that were not clearly relevant to the
analysis were excluded. After diligently reading the full
text of the remaining 122 studies, 64 studies were ex-
cluded because they did not meet the inclusion criteria.
Consequently, 58 observational studies [11–68] were
included for the meta-analysis.
Fig. 1 PRISMA Flow Diagram for Identification of Studies for Meta-analysis
Zhang et al. BMC Public Health  (2016) 16:216 Page 3 of 15
Table 1 Characteristics of included studies
Study Regiona Study instrumentb N Population (age) F/(F + M) Sampling method Ethnicity
Range x  s Groupc
Huang He, 2013 [33] CLDA Q 470 NA 20.09 ± 1.33 CS 0.504 Randomized Han
Ma Xiaojing, 2013 [12] EDA IAQ 1451 NA 45.1 ± 10.8 A 1 Convenience Mixed
He Mei, 2011 [41] CLDA Q 10,611 18–82 38.02 ± 9.57 A 1 Convenience Han
Cui Bo, 2010 [13] EDA IAQ 1160 15–59 35.66 ± 11.72 A 1 Randomized Mixed
He Xin, 2010 [29] NA SAQ 903 16–26 19.14 ± 1.01 CS 0.52 Cluster Han
Xu Jing, 2014 [11] CLDA Q 353 18–24 20.96 CS 0.683 Cluster Han
Feng Suwen, 2010 [46] EDA Q 1432 18–50 35.3 A 1 Cluster Han
Yan Jun, 2013 [43] WUDA IAQ 1681 30–49 NA A 1 Cluster Han
Long Xiange, 2011 [21] EDA Q 286 NA 18.5 CS NA Convenience Han
Hu Haishan, 2014 [28] EDA Q 542 31–60 41.57 ± 5.77 P 0.685 Cluster Mixed
Wu Ying, 2011 [25] EDA IAQ 489 15–50 NA A 1 Randomized Han
Li Juan, 2011 [14] EDA IAQ 160 NA 36.55 ± 9.59 A 0.738 Randomized Mixed
Fan Baojian, 2009 [23] EDA Q 962 19–72 43.38 ± 8.29 A 1 Cluster Mixed
Xiao Wei, 2009 [45] NA Q 378 21–74 36.19 A 1 Convenience Han
Wang Xuemin, 2012 [15] WUDA IAQ 2269 25–73 43.54 ± 7.67 A 1 Cluster Han
Shao Shujuan, 2013 [17] EDA Q 594 ≤60 36.02 ± 10.54 A 1 Randomized Han
Xu Wenyu, 2013 [18] EDA Q 3000 20–30 A 1 Convenience Han
Ma Dong, 2013 [40] NA Q 258 17–24 19.23 ± 0.89 CS 0.55 Cluster Han
Zhou Lixia, 2011 [42] EDA IAQ 752 16–55 NA A 1 Randomized Han
Huang Yanhua, 2014 [39] EDA Q 378 15–50 NA A 0.5 Randomized Han
Wang Haiqiu, 2011 [31] CLDA Q 257 20–53 33.6 ± 0.5 A 1 Randomized Han
Ma Dong, 2012 [30] CLDA Q 198 20–54 31.8 ± 7.0 A 0.89 Convenience Han
Yao Chenglian, 2012 [19] EDA Q 1198 16–65 NA A 1 Convenience Han
Xamxinuer Ablimit, 2009 [26] WUDA Q 245 23–85 48.8 A 1 Convenience Mixed
Xu Lina, 2013 [22] NA Q 1666 15–59 NA A 1 Randomized Han
Zhang Hui, 2014 [37] CLDA Q 341 32–50 39.56 ± 3.47 P 0.63 Cluster Han
Yu Jing, 2013 [44] CLDA Q 750 15–59 35.75 ± 9.4 A 1 Randomized Han
Guzalnur Abduxkur, 2012 [32] WUDA IAQ 560 NA NA A 0 Convenience Mixed
Cai Jing, 2013 [24] WUDA Q 648 NA NA A 0 Randomized Mixed
Li Li, 2010 [27] WUDA Q 1989 16–59 NA A 1 Cluster Mixed
Ying Wen, 2014 [35] CLDA Q 1878 17–25 NA CS 0.679 Randomized Mixed
Zhang Shaokai, 2013 [38] NA Q 2895 NA 40.4 ± 4.68 P 0.628 Cluster Mixed
Wang Shaoming, 2014 [20] NA Q 3368 NA 19.82 ± 1.31 CS 0.51 Randomized Mixed
Yan Hong, 2013 [16] EDA SAQ 360 18–36 25.1 ± 3.5 A 1 Convenience Mixed
Li Jing, 2009 [34] NA Q 6024 14–59 34.6 ± 1.7 A 1 Cluster Han
Zhao Fanghui, 2012 [36] NA Q 11,681 NA 34 ± 11.8 A 0.705 Randomized Han
Ayizuoremu · mutailipu, 2015 [64] WUDA Q 1900 16–60 NA A 1 Cluster Mixed
Zeng Xiaomin, 2015 [55] EDA SAQ 2004 NA NA C 1 Cluster Han
Wang Ling, 2015 [49] CLDA Q 125 18–23 20.5 C 1 Convenience Han
Liu Qiong, 2015 [57] CLDA Q 590 14–20 15.34 ± 1.3 C 0.91 Convenience Han
She Qian, 2015 [59] EDA IAQ 209 19–45 NA A 1 Randomized Han
Chen Ling, 2015 [50] NA IAQ 300 21–28 24 ± 0.8 C 1 Randomized Han
Cheng Lihong, 2015 [51] EDA Q 1256 19–55 NA A 1 Convenience Han
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Study characteristics
We included 58 individual studies [11–68] representing
19 provinces and municipalities in Mainland China
(Table 1). Eighty-three thousand, seven hundred and
five participants were interviewed, the majority of
which were females. Nearly all the studies were pub-
lished after 2009, and 38 studies were published in the
recent three years. A questionnaire survey was con-
ducted for all the studies included in the analysis, 12
of which were interview-administered, while nine were
self-administered questionnaires (Table 1). After con-
ducting a quality assessment on the included studies,
51 studies were categorized as grade A, and seven as
grade B (Table 2).
Awareness and knowledge of HPV vaccine
Awareness and knowledge of HPV vaccination among
different populations were reported in 43 and 21 studies,
respectively. The pooled awareness rate and knowledge
rate concerning HPV vaccination was 15.95 % (95 % CI:
12.87–19.29, I2 = 98.9 %), and 17.55 % (95 % CI: 12.38–
24.88, I2 = 99.8 %), respectively (Table 3). Figures 2 and 3
show forest plots of meta-analysis for HPV vaccine
awareness and knowledge in mainland China.
Acceptability of HPV vaccination
We explored the acceptability of HPV vaccination for
individuals and their daughters. Thirty-five studies ad-
dressed participants’ willingness to be vaccinated, while
12 studies addressed the willingness of parents to get
their daughters vaccinated. We found that the willing-
ness of participants to be vaccinated was 67.25 % (95 %
CI: 58.75–75.21, I2 = 99.8 %) while their willingness to
get their daughters vaccinated was 60.32 % (95 % CI:
51.25–69.04, I2 = 99.2 %) (Table 3). Figures 4 and 5 show
forest plots of meta-analysis for acceptability of HPV
vaccination (for themselves and their daughters) in
mainland China.
Reasons for unwillingness to be HPV vaccinated
Reasons for the unwillingness of individuals to be HPV
vaccinated varied across studies. Nineteen studies ex-
plored reasons for participants’ reluctance to HPV vac-
cination. Among participants who were unwilling to be
vaccinated, 33.63 % (95 % CI: 27.50–40.05, I2 = 97.2 %)
respondents believed that they had a low risk of develop-
ing HPV infection, genital warts, or even cervical cancer.
Other respondents were worried about the limited use
of HPV vaccine in China (36.31 %; 95 % CI: 29.67–43.22,
I2 = 97.7 %). Respondents who were concerned with the
safety and the efficacy of HPV vaccination accounted for
50.46 % (95 % CI: 40.00–60.89, I2 = 96.6 %) and 30.18 %
(95 % CI: 23.96–36.79, I2 = 97.3 %), respectively. Partici-
pants who questioned the source of the vaccine and
communicated a concern regarding the high price of the
vaccine were 32.17 % (95 % CI: 21.14–43.30, I2 = 99.2 %)
and 23.72 % (95 % CI: 13.64–35.59, I2 = 98.2 %), respect-
ively (Table 3).
Table 1 Characteristics of included studies (Continued)
Zhu Qiaoyang, 2015 [58] EDA Q 362 18–66 42.2 ± 6.3 A 1 Convenience Han
Lei Juhong, 2015 [61] EDA Q 300 15–64 NA A NA Randomized Han
Zhao Bixia, 2015 [63] CLDA Q 138 25–50 NA A NA Convenience Han
Xie Wenliu, 2015 [48] CLDA Q 192 15–70 NA A 0.51 Convenience Han
Zhou Yanqiu, 2015 [47] EDA SAQ 600 ≥21 NA A NA Convenience Han
Meng Liping, 2015 [60] EDA SAQ 1652 20–65 38.09 ± 8.21 A NA Cluster Han
Zou Huachun, 2015 [53] EDA SAQ 368 NA NA A 0 Convenience Han
Zou Huachun, 2015 [52] EDA SAQ 351 16–25 NA C 0.524 Cluster Mixed
Gu Can, 2015 [62] CLDA Q 117 19–23 20.8 ± 1 C 1 Convenience Han
Wang Wei, 2015 [56] EDA Q 360 NA 41.77 ± 3.33 P 0.522 Cluster Mixed
Abida Abudukadeer, 2015 [65] WUDA IAQ 5000 20–51 NA A 1 Convenience Mixed
Zhang Shaokai, 2015 [54] CLDA Q 2895 NA 40.4 ± 4.68 P 0.628 Cluster Mixed
Pan Xiongfei, 2015 [66] CLDA Q 1878 17–25 20.8 ± 1.3 C 0.679 Convenience Mixed
Fu Chunjing, 2015 [67] CLDA SAQ 605 18–26 21.6 ± 1 C 0.689 Randomized Mixed
Hu Shangying, 2105 [68] EDA IAQ 316 18–25 23.2 ± 1.7 C 1 Cluster Han
aEDA eastern developed areas, such as Beijing (city), Tianjin (city), Shanghai (city), Dalian (city), Shandong(province), Jinan(city), Zhejiang(province), Hangzhou(city),
Ningbo(city), Jiangsu(province), Wuxi(city), Guangdong(province), Guangzhou(city), Shenzhen(city), Dongguan(city), Zhongshan(city), CLDA central less
derdeveloped areas, such as Liaoning(province), Tangshan(city), Xi’an(city), Wuhan(city), Hunan(province), Hengyang(city), Chongqing(city), Chengdu(city),
Yunnan(province), National, southwest China, WUDA western or undeveloped areas, such as Gansu, Xinjiang and Shanxi
bIAQ interview-administered questionnaire, SAQ self-administered questionnaire, N not specified questionnaire
cA adults, P parents, CS college students
NA not available
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Reasons for unwillingness of parents to vaccinate their
daughters
Seven studies explored the reasons for participants’ re-
luctance to get their daughters HPV vaccinated. Among
them, 32.61 % (95 % CI: 22.03–44.18, I2 = 94.5 %) re-
spondents were concerned regarding the limited use of
HPV vaccine in China to date. Some respondents
(68.19 %; 95 % CI: 53.13–81.52, I2 = 98.6 %) doubted
the safety and efficacy of the HPV vaccine. Only
17.24 % (95 % CI: 13.87–20.90, I2 = 82.8 %) of the
respondents doubted the vaccine source. In addition,
28.37 % (95 % CI: 13.69–45.90, I2 = 99 %) of the respon-
dents considered their children to be too young for
vaccination (Table 3).
Subgroup analysis and meta-regression
A subgroup analysis indicated that the awareness of
HPV vaccine differed across sexes (P = 0.033), ethnicities
(P = 0.017), and regions (P = 0.031). We observed a
higher HPV vaccine awareness among the female popu-
lation (17.39 %; 95 % CI: 13.06–22.20, I2 = 98.8 %) and
mixed population (18.55 %; 95 % CI:14.14–23.42, I2 =
98.8 %) relative to the male population (1.82 %; 95 % CI:
0.50–11.20, I2 = 98.5 %). We also found that populations
of mixed ethnicity have lower HPV vaccine awareness
(9.61 %; 95 % CI: 5.95–14.03, I2 = 99.0 %) compared to
population of Han (20.17 %; 95 % CI: 16.42–24.20, I2 =
98.3 %). Among different regions, the HPV vaccine
awareness was higher in EDA (17.57 %; 95 % CI: 13.36–
Table 2 Quality assessment of included studies
Studies 1 2 3 4 5 6 7 Scores Grade
Huang He, 2013 [33] 1 1 1 1 1 1 1 7 A
Ma Xiaojing, 2013 [12] 1 1 0 1 1 1 1 6 A
He Mei, 2011 [41] 1 0 0 0 1 1 1 4 B
Cui Bo, 2010 [13] 1 1 1 1 1 1 1 7 A
He Xin, 2010 [29] 1 1 1 1 1 1 1 7 A
Xu Jing, 2014 [11] 1 1 1 1 1 1 1 7 A
Feng Suwen, 2010 [46] 1 1 0 1 1 1 1 6 A
Yan Jun, 2013 [43] 1 1 0 1 1 1 1 6 A
Long Xiange, 2011 [21] 1 0 1 0 1 1 1 5 B
Hu Haishan, 2014 [28] 1 1 0 1 1 1 1 6 A
Wu Ying, 2011 [25] 1 0 1 1 1 1 1 6 A
Li Juan, 2011 [14] 1 1 1 1 1 1 1 7 A
Fan Baojian, 2009 [23] 1 0 1 1 1 1 1 6 A
Xiao Wei, 2009 [45] 1 1 0 0 1 1 1 5 B
Wang Xuemin, 2012 [15] 1 1 0 1 1 1 1 6 A
Shao Shujuan, 2013 [17] 1 0 0 1 1 1 1 5 B
Xu Wenyu, 2013 [18] 1 1 1 0 1 1 1 6 A
Ma Dong, 2013 [40] 1 1 1 0 1 1 1 6 A
Zhou Lixia, 2011 [42] 1 1 1 1 1 1 1 7 A
Huang Yanhua, 2014 [39] 1 0 1 1 1 1 1 6 A
Wang Haiqiu, 2011 [31] 1 1 1 0 1 1 1 6 A
Ma Dong, 2012 [30] 1 1 1 0 1 1 1 6 A
Yao Chenglian, 2012 [19] 1 0 0 1 1 1 1 5 B
Xamxinuer Ablimit, 2009 [26] 1 1 0 0 1 1 1 5 B
Xu Lina, 2013 [22] 1 1 0 1 1 1 1 6 A
Zhang Hui,2014 [37] 1 1 1 1 1 1 1 7 A
Yu Jing, 2013 [44] 1 1 0 1 1 1 1 6 A
Guzalnur Abduxkur, 2012 [32] 1 1 0 0 1 1 1 5 B
Cai Jing, 2013 [24] 1 1 0 1 1 1 1 6 A
Li Li, 2010 [27] 1 1 0 1 1 1 1 6 A
Ying Wen, 2014 [35] 1 1 1 1 1 1 1 7 A
Zhang Shaokai, 2013 [38] 1 1 1 1 1 1 1 7 A
Wang Shaoming, 2014 [20] 1 1 1 1 1 1 1 7 A
Yan Hong, 2013 [16] 1 1 0 1 1 1 1 6 A
Li Jing, 2009 [34] 1 1 1 1 1 1 1 7 A
Zhao Fanghui, 2012 [36] 1 1 0 1 1 1 1 6 A
Ayizuoremu · mutailipu, 2015 [64] 1 1 0 1 1 1 1 6 A
Zeng Xiaomin, 2015 [55] 1 0 1 1 1 1 1 6 A
Wang Ling, 2015 [49] 1 1 0 1 1 1 1 6 A
Liu Qiong, 2015 [57] 1 1 1 1 1 1 1 7 A
She Qian, 2015 [59] 1 1 1 1 1 1 1 7 A
Chen Ling, 2015 [50] 1 1 1 1 1 1 1 7 A
Cheng Lihong, 2015 [51] 1 1 1 1 1 1 1 7 A
Zhu Qiaoyang, 2015 [58] 1 0 1 1 1 1 1 6 A
Table 2 Quality assessment of included studies (Continued)
Lei Juhong, 2015 [61] 1 1 1 1 1 1 1 7 A
Zhao Bixia, 2015 [63] 1 0 1 1 1 1 1 6 A
Xie Wenliu, 2015 [48] 1 1 1 1 1 1 1 7 A
Zhou Yanqiu, 2015 [47] 1 1 1 1 1 1 1 7 A
Meng Liping, 2015 [60] 1 1 1 1 1 1 1 7 A
Zou Huachun, 2015 [53] 1 1 1 1 1 1 1 7 A
Zou Huachun, 2015 [52] 1 1 1 1 1 1 1 7 A
Gu Can, 2015 [62] 1 1 0 1 1 1 1 6 A
Wang Wei, 2015 [56] 1 1 1 1 1 1 1 7 A
Abida Abudukadeer, 2015 [65] 1 1 1 1 1 1 1 7 A
Zhang Shaokai, 2015 [54] 1 1 0 1 1 1 1 6 A
Pan Xiongfei, 2015 [66] 1 1 1 1 1 1 1 7 A
Fu Chunjing, 2015 [67] 1 1 1 1 1 1 1 7 A
Hu Shangying, 2105 [68] 1 1 0 1 1 1 1 6 A
For the second index; “data collection strategy”, we considered the study as
reasonable when it satisfied one of the following criteria: 1) study purpose and
survey contents were explained to participants before the survey, 2) investigators
reviewed the questionnaire in terms of the clarity of language and completeness
of the questionnaire
For the fourth index, “representativeness of the sample,” we recognized the
sample as a good representative when it met one of the following requirements:
1) specific inclusion and exclusion criteria were provided, 2) a reasonable
sampling method was used
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22.21, I2 = 98.0 %) and CLDA (17.78 %; 95 % CI: 12.18–
24.19, I2 = 97.6 %) compared to WUDA (1.80 %; 95 %
CI: 0.02–6.33, I2 = 98.9 %). Subgroup analysis revealed
that acceptability to be vaccinated varied among studies
conducted using different sampling methods (P = 0.022).
The acceptability of vaccination among cluster-sampled
population (72.45 %; 95 % CI: 52.22–88.76, I2 = 99.9 %)
was higher compared to the convenience-sampled popu-
lation (53.53 %; 95 % CI: 41.95–64.92, I2 = 99.5 %). The
subgroup analysis showed that acceptability for parents
to vaccinate their daughters differed across ages (P =
0.014) and sampling methods (P = 0.038). General adult
population (64.72 %; 95 % CI: 55.57–73.36, I2 = 99.2 %)
was more willing to vaccinate their daughters than par-
ent population (33.78 %; 95 % CI: 26.26–41.74, I2 =
88.3 %). Randomized sampling method showed a higher
acceptability for vaccination of daughters (72.75 %; 95 %
CI: 67.66–77.56, I2 = 92.9 %) compared to cluster
sampling method (48.54 %; 32.37–64.88, I2 = 99.4 %)
(Table 4). Meta-regression analysis was also performed
but failed to explain the source of heterogeneity.
Publication bias
Egger’s test was performed to assess the publication bias.
The results did not show evidence of publication bias
(all P > 0.05) (Table 3).
Discussion
This is the first meta-analysis study conducted for the
assessment of HPV vaccine related awareness,
knowledge and acceptability among the Chinese popula-
tion. Our meta-analysis identified low awareness
(15.95 %) and low knowledge (17.55 %) of HPV vaccine
among the Chinese population. The rates were lower
compared to many other countries. Studies conducted in
Turkey showed that HPV vaccine awareness among
undergraduate students in Turkey was 44.5 % [69], while
27.9 % of respondents knew that HPV vaccines can pre-
vent cervical cancer [70]. In addition, the HPV vaccine
awareness rates were found to be in the 67.1–71.3 %
range in the USA, UK and Australia [71]. The higher
awareness rate of HPV vaccine and related knowledge in
these countries may be due to the intervention programs
and increased media coverage [72–74]. The low level of
HPV vaccine awareness may greatly influence its promo-
tion in China. In subgroup analysis, the pooled rate of
HPV vaccine awareness was higher among females
(17.39 %) and mixed population (18.55 %) compared to
the male population (1.82 %). In the Chinese tradition,
males play an important role in decision-making in the
family, the low awareness of HPV vaccine may influence
the acceptability of vaccination for their daughters [53].
We also found that populations of mixed ethnicity have
lower HPV vaccine awareness rates (9.61 %) compared
to population of Han (20.17 %). In addition, a study in
England showed that HPV vaccine awareness was lower
among ethnic minority groups (6–18 %) compared to
white women (39 %), and that ethnic minorities have
lower uptake of vaccination [75, 76]. These findings
suggest that potential ethnic inequalities and cultural
Table 3 The results of pooled rates of studied items (Supplementary Material: Additional file 1: "Availability of Data and Materials")






Awareness 43 15.95 (12.87–19.29) 98.9 >0.05
Knowledge 21 17.55 (12.38–24.88) 99.8 >0.05
Acceptability 35 67.25 (58.75–75.21) 99.8 >0.05
Reasons for unwillingness to be HPV vaccinated
Assumed low risk 14 33.63 (27.50–40.05) 97.2 >0.05
Limited use to date 14 36.31 (29.67–43.22) 97.7 >0.05
Safety 10 50.46 (40.00–60.89) 96.6 >0.05
Efficacy 14 30.18 (23.96–36.79) 97.3 >0.05
Vaccine source 11 32.17 (21.14–43.30) 99.2 >0.05
High price 6 23.72 (13.64–35.59) 98.2 >0.05
Acceptability (for daughters) 12 60.32 (51.25–69.04) 99.2 >0.05
Reasons for unwillingness of parents to vaccinate their daughters
Limited use to date 4 32.61 (22.03–44.18) 94.5 >0.05
Safety and efficacy 7 68.19 (53.13–81.52) 98.6 >0.05
Vaccine source 7 17.24 (13.87–20.90) 82.8 >0.05
Too young to vaccinate 7 28.37 (13.69–45.90) 99 >0.05
The pooled rate and 95 % CI are from random effects model
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barriers should be identified for the prevention of cer-
vical cancer [76]. Among different regions, HPV vaccine
awareness was higher in EDA (17.57 %) and CLDA
(17.78 %) compared to WUDA (1.80 %). In fact, eastern
and central areas benefit from abundant healthcare re-
sources and strong economies compared to western or
some undeveloped regions. The difference between
different geographical areas in China revealed that
socio-economic status is a factor that influences the
HPV vaccine awareness.
In addition, we found a relative high acceptability of
HPV vaccination (67.25 % for themselves and 60.32 % for
daughters). However, this rate declines in the high-end of
the level across the world (59 % to 100 %) [77–79]. In
Fig. 2 Forest Plot of meta-analysis for HPV vaccine awareness in mainland China, the pooled rate and 95 % CI in the article are from random
effects model due to significant heterogeneity which was measured by I2 statistics
Zhang et al. BMC Public Health  (2016) 16:216 Page 8 of 15
Fig. 3 Forest Plot of meta-analysis for HPV vaccine knowledge in mainland China, the pooled rate and 95 % CI in the article are from random effects
model due to significant heterogeneity which was measured by I2 statistics
Fig. 4 Forest Plot of meta-analysis for acceptability of HPV vaccination(for themselves) in mainland China, the pooled rate and 95 % CI in the
article are from random effects model due to significant heterogeneity which was measured by I2 statistics
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subgroup analysis, the acceptability to be vaccinated
among cluster-sampled population (72.45 %) was higher
than convenience-sampled population (53.53 %), and ran-
domized sampling method (72.75 %) showed a higher ac-
ceptability for vaccination of daughters compared to
cluster sampling method (48.54 %). This is an indication
that acceptability of vaccination among the population
may be higher if rigorous sampling methods, such as ran-
domized sampling method, are used. Subgroup analysis
showed that parental acceptability of vaccination
(33.78 %) was lower compared to the general adult popu-
lation (64.72 %). Moreover, the acceptability rate (33.78 %)
was lower compared to similar studies conducted in other
countries. A similar study in Sweden reported that 76 % of
participated parents were willing to vaccinate their daugh-
ters [80]. In addition, studies in Africa showed that par-
ents with good knowledge of HPV vaccine were more
willing to vaccinate their children than those with poor
knowledge [81]. Population’s attitude and acceptance to-
ward HPV vaccination is an important determinant for
the success of HPV vaccine promotion in China in the
future, which necessitates, the identification of the
main obstacles concerning the acceptability of vaccin-
ation among the Chinese population.
The primary obstacles concerning vaccination accept-
ability for responders were the safety and efficacy of the
HPV vaccine. HPV vaccines have been proved safe and
efficient against HPV infection [82, 83]. WHO recom-
mended HPV vaccination for both young women and
men before the onset of sexual activity [84]. In recent
years, many studies have investigated HPV vaccine safety
and adverse events. Both of the HPV vaccines are related
to high rates of injection site reactions, such as pain, swell-
ing and redness which maybe due to a possible VLP-
related (VLP, Virus-like particles) inflammation process
[85]. However, these outcomes are usually for a short dur-
ation and recovery is quick [86]. Most reported adverse
events were mild or moderate in intensity [87–98], and
serious vaccination-related adverse events, such as ana-
phylaxis, are rare [86]. Similarly, other studies reported
that there were no vaccine related deaths in the included
studies [99]. Furthermore, a review concluded that the
prophylactic vaccines against HPV appear safe based on
the assessment of reported adverse events by governmen-
tal databases and independent researchers [100].
Sufficient scientific evidence has clarified many of the
misunderstandings related to vaccine safety, however,
the concerns related to vaccination are still increasing
[101]. Public confidence in vaccines is particularly im-
portant. If vaccination is not trusted, the hesitance to be
vaccinated may lead to delay and refusal, resulting in the
disintegration of related research and delivery programs,
and may even result in disease outbreak [102, 103]. The
segmented information from media may amplify vaccine
related concerns, resulting in the circulation of anxiety
among the public [104]. It is the responsibility of the
healthcare providers to rectify the misconceptions
related to vaccination among the population, while
acknowledging parents' concerns, updating their know-
ledge on vaccine related health information by paying
close attention to the latest scientific research, and allo-
cating sufficient time to instruct the concerned popula-
tion on vaccine safety [101].
Mainland China has not introduced HPV vaccination
into the routine immune vaccination program, experi-
ences from other countries that implemented HPV vac-
cination program can be taken as an example. In many
counties, an organized vaccination program is recom-
mended to increase the vaccination coverage. It is now
widely believed that the most urgent public-health issue
is to increase HPV vaccination coverage and improve
completion of the vaccination schedule, especially
among sexually active females [105]. Thus, many studies
further explored means to boost vaccination rates. An
Fig. 5 Forest Plot of meta-analysis for acceptability of HPV vaccination(for daughters) in mainland China, the pooled rate and 95 % CI in the article
are from random effects model due to significant heterogeneity which was measured by I2 statistics
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analysis showed that HPV vaccination rate could not be
increased solely by educational intervention. A research
conducted in America showed that a provider-centered
PICME (Performance Improvement Continuing Medical
Table 4 The results of subgroup analysis by characteristics of
the population
Subgroups No. of studies Incidence %
(95 % CI)
I2 (%) P value
Awareness (all studies)
Age 0.698
CS 12 19.07 (11.72,27.71) 99.0
A 27 15.14 (11.11,19.68) 99.1
P 5 15.62 (13.13,18.28) 85.4
Sex 0.033
Fa 23 17.39 (13.06,22.20) 98.8
F, Ma 17 18.55 (14.14,23.42) 98.8
Mb 3 1.82 (0.50,11.20) 98.5
Sample method 0.504
Randomized 16 18.88 (13.60,24.80) 99.0
Cluster 16 13.74 (7.66,21.24) 99.1
Convenience 12 16.03 (12.12,20.36) 97.7
Ethnicity 0.017
Han 29 20.17 (16.42,24.20) 98.3
Mixed 15 9.61 (5.95,14.03) 99.0
Region 0.031
EDAa 20 17.57 (13.36,22.21) 98.0
CLDAa 12 17.78 (12.18,24.19) 97.6
WUDAb 5 1.80 (0.02,6.33) 98.9
Knowledge (all studies)
Age 0.171
CS 10 40.94 (20.11,63.64) 99.8
A 11 15.52 (10.22,21.69) 98.7
P 1 16.27
Sex 0.841
F 13 27.2 (17.56,38.07) 99.5
F, M 9 24.51 (10.28,42.45) 99.7
M 0
Sample method 0.757
Randomized 11 29.87 (13.02,50.19) 99.7
Cluster 7 19.16 (12.41,26.98) 98.7
Convenience 0
Ethnicity 0.893
Han 14 25.40 (14.41,38.28) 99.4
Mixed 8 27.46 (13.87,43.62) 99.8
Region 0.837
EDA 8 19.58 (11.76,28.82) 98.6
CLDA 9 27.80 (11.97,47.20) 99.7
WUDA 2 13.96 (2.44,32.70) 99.7
Acceptability (for themselves)
Age 0.338
Table 4 The results of subgroup analysis by characteristics of
the population (Continued)
CS 10 71.71 (64.06,78.77) 97.9
A 24 64.82 (52.80,75.95) 99.9
P 2 44.92 (26.00,64.63) 98.7
Sex 0.208
F 21 68.50 (54.40,81.05) 99.9
F, M 15 61.65 (52.47,70.43) 99.4
M 0
Sample method 0.022
Randomized 12 70.42 (63.63,76.79) 98.8
Clustera 12 72.45 (52.22,88.76) 99.9
Convenienceb 12 53.53 (41.95,64.92) 99.5
Ethnicity 0.939
Han 24 65.14 (53.62,75.83) 99.8
Mixed 12 66.76 (51.25,80.60) 99.7
Region 0.407
EDA 14 65.31 (54.68,75.21) 99.2
CLDA 12 64.10 (46.56,79.87) 99.7




Aa 10 64.72 (55.57,73.36) 99.2
Pb 3 33.78 (26.26,41.74) 88.3
Sex 0.068
F 8 67.04 (57.46,75.96) 99.2
F, M 4 46.06 (27.07,65.66) 97.6
M 0
Sample method 0.038
Randomizeda 5 72.75 (67.66,77.56) 92.9
Clusterb 6 48.54 (32.37,64.88) 99.4
Convenience 3 56.36 (34.63,76.88) 98.8
Ethnicity 0.253
Han 8 57.84 (47.89,67.48) 99.5
Mixed 6 61.04 (44.36,76.50) 99.3
Region 0.689
EDA 6 59.03 (41.51,75.44) 98.9
CLDA 4 56.36 (37.18,74.60) 99.3
WUDA 2 51.49 (33.81,68.97) 99.3
There were significant differences in groups with different letters (P < 0.05)
The pooled rate and 95 % CI are from random effects model
A adults, P parents, CS college students
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Education) intervention, which includes repeated
communication, focused education, and individualized
feedback, proved an effective measure for sustained im-
provement of vaccination rates [106]. Another study
showed obvious differences between adopters and non-
adopters via in-depth interviews, emphasizing that vacci-
nated women benefit from supportive social influences
whereas unvaccinated women’s concerns regarding the
safety and efficacy of short- and long-term vaccination
was influenced by their interpersonal network [107].
Further research to perfect the existing HPV vaccines
is needed. Moreover, as a measure of primary preven-
tion, HPV vaccination should be performed alongside
cervical screening (secondary prevention) as a clear
strategy for the prevention of cervical cancer.
The strength of our analysis is that the evaluation of the
recently published papers about HPV vaccination among
the Chinese population allowed us to offer evidence-based
advice for the implementation of HPV vaccination in
Mainland China in future. However, there were some limi-
tations in this study. Obvious heterogeneity existed in the
meta-analysis. We tried to perform meta-regression ana-
lysis to explain the source of heterogeneity, however, sig-
nificant heterogeneity remained unexplained after an
exploration of the relative factors, such as sampling
method and population characteristics. In fact, for observa-
tional studies that involve proportions, substantial hetero-
geneity is a common dilemma [108]. Although a
theoretical framework was designed, it is difficult to ensure
that all the original studies used rigorous testing and valid-
ation for the investigation as previously outlined in real cir-
cumstances. These variations and constraints may account,
at least partly, towards the observed heterogeneity. In
addition, measures of studied factors were inconsistent
among studies, and it is difficult to clarify the inconsisten-
cies due to the difference of measurements across included
studies or true variability among the population [109].
Conclusions
In conclusion, this meta-analysis proved low HPV vac-
cine awareness and knowledge among the Chinese
population. HPV vaccine awareness differed across
sexes, ethnicities, and regions. However, given the lim-
ited quality and number of included studies, future
studies with improved design are necessary for the veri-
fication of our findings.
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